Aura Biosciences gets FDA fast track status for belzupacap sarotalocan

By on    Pharma Industry News  

Aura Biosciences gets FDA fast track status for belzupacap sarotalocan

Aura Biosciences has secured fast track designation for belzupacap sarotalocan (AU-011) from the US Food and Drug Administration (FDA) for the treatment of non-muscle invasive bladder cancer (NMIBC). Belzupacap sarotalocan is the first virus-like drug conjugate (VDC) being developed by the American biotech company for various oncology indications. Dr. Mark De Rosch — Aura Biosciences […]

Aura Biosciences raises $80m for VDC therapies for cancers

By on    Pharma Industry News  

Aura Biosciences raises $80m for VDC therapies for cancers

Aura Biosciences, a portfolio company of UK-based Arix Bioscience, has raised $80 million in a new funding round for developing virus-like drug conjugate (VDC) therapies for multiple oncology indications. The funding round of the US-based clinical-stage oncology company was led by Matrix Capital Management and Surveyor Capital, a Citadel company. New investors such as Rock […]